Variation in the fibroblast growth factor 23 (FGF23) gene associates with serum FGF23 and bone strength in infants

被引:1
|
作者
Enlund-Cerullo, Maria [1 ,2 ,3 ,4 ]
Holmlund-Suila, Elisa [1 ,2 ,4 ]
Valkama, Saara [1 ,2 ,4 ]
Hauta-alus, Helena [1 ,2 ,4 ,5 ,6 ,7 ]
Rosendahl, Jenni [1 ,2 ,4 ]
Andersson, Sture [1 ,2 ]
Pekkinen, Minna [1 ,2 ,3 ,4 ]
Makitie, Outi [1 ,2 ,3 ,4 ,8 ,9 ]
机构
[1] Univ Helsinki, Childrens Hosp, Pediat Res Ctr, Helsinki, Finland
[2] Helsinki Univ Hosp, Childrens Hosp, Pediat Res Ctr, Helsinki, Finland
[3] Folkhalsan Inst Genet, Folkhalsan Res Ctr, Helsinki, Finland
[4] Univ Helsinki, Fac Med, Res Program Clin & Mol Metab, Helsinki, Finland
[5] Natl Inst Hlth & Welf THL, Publ Hlth Res, Helsinki, Finland
[6] Oulu Univ Hosp, PEDEGO Res Unit, MRC Oulu, Oulu, Finland
[7] Univ Oulu, PEDEGO Res Unit, MRC Oulu, Oulu, Finland
[8] Karolinska Univ Hosp, Dept Mol Med & Surg, Stockholm, Sweden
[9] Karolinska Univ Hosp, Karolinska Inst, Ctr Mol Med, Clin Genet, Stockholm, Sweden
基金
瑞典研究理事会; 芬兰科学院;
关键词
FGF23; genetic variation; vitamin D; bone strength; infants (0-24 months); DOMINANT HYPOPHOSPHATEMIC RICKETS; PHYSIOLOGICAL-ROLE; MINERAL DENSITY; VITAMIN-D; PHOSPHATE; MUTATIONS; CHILDREN;
D O I
10.3389/fgene.2023.1192368
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Introduction: The effects of genetic variation in fibroblast growth factor 23 (FGF23) are unclear. This study explores the associations of single-nucleotide polymorphisms (SNPs) of FGF23 with phosphate and vitamin D metabolism and bone strength in early childhood. Methods: The study is part of the vitamin D intervention in infant (VIDI) trial (2013-2016), in which healthy term infants born to mothers of Northern European origin received vitamin D-3 supplementation of 10 or 30 mu g/day from 2 weeks to 24 months of age (ClinicalTrials.gov NCT01723852). Intact and C-terminal FGF23 (cFGF23), 25-hydroxyvitamin D (25-OHD), parathyroid hormone, phosphate, and peripheral quantitative computed tomography (pQCT)-derived bone strength parameters were analyzed at 12 and 24 months. The study included 622 VIDI participants with genotyping data on FGF23 SNPs rs7955866, rs11063112, and rs13312770. Results: Rs7955866 minor allele homozygotes had lowest cFGF23 at both time-points (mixed model for repeated measurements, p(variant) = 0.009). Minor alleles of rs11063112 were associated with a greater age-related decrease in phosphate concentration (p(interaction) = 0.038) from 12 to 24 months. Heterozygotes of rs13312770 had the greatest total bone mineral content (total BMC), cross-sectional area (total CSA), and polar moment of inertia (PMI) at 24 months (ANOVA p = 0.005, 0.037, and 0.036, respectively). Rs13312770 minor alleles were associated with a greater increase of total BMC, but a smaller increase of total CSA and PMI, during follow-up (p(interaction) <0.001, 0.043, and 0.012, respectively). Genotype of FGF23 did not modify 25-OHD. Conclusion: The study finds that genetic variation in FGF23 modifies cFGF23, phosphate, and pQCT-derived bone strength parameters from 12 to 24 months of age. These findings potentially promote an understanding of the regulation of FGF23 and its role in bone metabolism and temporal changes thereof during early childhood.
引用
收藏
页数:18
相关论文
共 50 条
  • [1] Fibroblast Growth Factor 23 (FGF23) and the kidney
    Tsagalis, George
    Psimenou, Erasmia
    Manios, Efstathios
    Laggouranis, Antonios
    INTERNATIONAL JOURNAL OF ARTIFICIAL ORGANS, 2009, 32 (04): : 232 - 239
  • [2] Fibroblast growth factor-23 (FGF23)
    White, Kenneth E.
    ENDOCRINE JOURNAL, 2010, 57 : S201 - S201
  • [3] Vitamin A regulates fibroblast growth factor 23 (FGF23)
    Rausch, Steffen
    Barholz, Michelle
    Foeller, Michael
    Feger, Martina
    NUTRITION, 2020, 79-80
  • [4] The couple fibroblast growth factor 23 (FGF23)/Klotho
    Prie, Dominique
    ANNALES DE BIOLOGIE CLINIQUE, 2015, 73 (03) : 299 - 304
  • [5] Fibroblast Growth Factor 23 (FGF23) and Disorders of PhosphateMetabolism
    Saito, Tasuku
    Fukumoto, Seiji
    INTERNATIONAL JOURNAL OF PEDIATRIC ENDOCRINOLOGY, 2009,
  • [6] Serum Fibroblast Growth Factor 23 (FGF23) in Patients with Rheumatoid Arthritis
    Sato, Hiroe
    Kazama, Junichiro James
    Murasawa, Akira
    Otani, Hiroshi
    Abe, Asami
    Ito, Satoshi
    Ishikawa, Hajime
    Nakazono, Kiyoshi
    Kuroda, Takeshi
    Nakano, Masaaki
    Narita, Ichiei
    INTERNAL MEDICINE, 2016, 55 (02) : 121 - 126
  • [7] Insulin suppresses the production of fibroblast growth factor 23 (FGF23)
    Baer, Ludmilla
    Feger, Martina
    Fajol, Abul
    Klotz, Lars-Oliver
    Zeng, Shufei
    Lang, Florian
    Hocher, Berthold
    Foeller, Michael
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2018, 115 (22) : 5804 - 5809
  • [8] The Measurement and Interpretation of Fibroblast Growth Factor 23 (FGF23) Concentrations
    Annemieke C. Heijboer
    Etienne Cavalier
    Calcified Tissue International, 2023, 112 : 258 - 270
  • [9] The Measurement and Interpretation of Fibroblast Growth Factor 23 (FGF23) Concentrations
    Heijboer, Annemieke C.
    Cavalier, Etienne
    CALCIFIED TISSUE INTERNATIONAL, 2023, 112 (02) : 258 - 270
  • [10] SERUM AND VASCULAR FIBROBLAST GROWTH FACTOR 23 (FGF23) ARE ASSOCIATED WITH VASCULAR CALCIFICATION
    Donate-Correa, Javier
    Martin-Nunez, Ernesto
    Hernandez-Carballo, Carolina
    Ferri, Carla
    Arevalo-Gomez, Miguel
    Gonzalez-Luis, Ainhoa
    Rodriguez-Lopez, Sergio
    Cerro-Lopez, Purificacion
    Lopez-Castillo, Angel
    Mora-Fernandez, Carmen
    Navarro-Gonzalez, Juan F.
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2021, 36